Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) EBITDA (2016 - 2017)

Historic EBITDA for Soleno Therapeutics (SLNO) over the last 5 years, with Q4 2017 value amounting to -$5.2 million.

  • Soleno Therapeutics' EBITDA fell 18361.53% to -$5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.2 million, marking a year-over-year decrease of 1749.07%. This contributed to the annual value of -$175.5 million for FY2024, which is 35011.03% down from last year.
  • According to the latest figures from Q4 2017, Soleno Therapeutics' EBITDA is -$5.2 million, which was down 18361.53% from -$2.6 million recorded in Q3 2017.
  • Soleno Therapeutics' EBITDA's 5-year high stood at -$559783.0 during Q4 2013, with a 5-year trough of -$5.2 million in Q4 2017.
  • Moreover, its 5-year median value for EBITDA was -$2.1 million (2016), whereas its average is -$2.3 million.
  • Per our database at Business Quant, Soleno Therapeutics' EBITDA tumbled by 25467.84% in 2015 and then soared by 6779.26% in 2017.
  • Soleno Therapeutics' EBITDA (Quarter) stood at -$559783.0 in 2013, then tumbled by 229.72% to -$1.8 million in 2014, then tumbled by 89.99% to -$3.5 million in 2015, then surged by 47.73% to -$1.8 million in 2016, then crashed by 183.62% to -$5.2 million in 2017.
  • Its EBITDA stands at -$5.2 million for Q4 2017, versus -$2.6 million for Q3 2017 and -$3.0 million for Q2 2017.